OSAHS
Conditions
Interventions
Group A:Administer placebo first, followed by dexmedetomidine, and then propofol. Each administration was separated by a 1-week elution period.
Group B:Administer placebo first, followed by propofol, and then dexmedetomidine. Each administration was separated by a 1-week elution period.
Group C:Administer dexmedetomidine first, followed by placebo, and then propofol. Each administration was separated by a 1-week elution period.
Group D:Administer dexmedetomidine first, followed by propofol, and then placebo. Each administration was separated by a 1-week elution period.
Group E:Administer propofol first, followed by placebo, and then dexmedetomidne. Each administration was separated by a 1-week elution period.
Group F:Administer propofol first, followed by dexmedetomidne, and then placebo. Each administration was separated by a 1-week elution period.
Sponsors
First Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Outpatients or inpatients diagnosed with OSAHS by PSG, including mild, moderate, and severe cases. 2. Aged between 18 and 65, of any gender. 3. No upper respiratory tract infection within the past 2 weeks. 4. Signed informed consent form (ICF).
Exclusion criteria
Exclusion criteria: 1. Allergy to dexmedetomidine or propofol, or any other contraindications to the use of these drugs. 2. Severe systemic illnesses with a high risk of inducing sleep (such as myocardial ischemia, heart failure, history of cerebral infarction, liver or kidney damage, etc.). 3. Morbid obesity (BMI > 35kg/m²). 4. Pulmonary diseases that affect respiration (such as chronic obstructive pulmonary disease, bronchial asthma, bullous pulmonary diseases, pneumothorax, etc.). 5. Current or previous long-term use of medication known to affect sleep and respiratory function (such as sedatives, antipsychotics) or drugs that affect muscle physiology (such as muscle relaxants). 6. Previous surgery for OSAHS, including tonsillectomy and/or adenoidectomy, UPPP, tongue base RF ablation, etc. 7. Sinus bradycardia, sick sinus syndrome, or atrioventricular block confirmed by electrocardiography. 8. Patients with prostatic hyperplasia or Urinary retention; 9. Pregnancy or lactation period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Upper airway collapsibility; | — |
Secondary
| Measure | Time frame |
|---|---|
| Dilator muscle compensation;Respiratory arousal threshold; | — |
Countries
China
Contacts
Public ContactRenqiang Ma
First Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed